Category Archives: Cell Medicine

University of Melbourne announce Stem Cells Discovery
Researchers have completed the study by using skin biopsies from patients with the rare genetic disease Friedreich Ataxia (FA). The discovery will allow for the development of new treatments for FA and related conditions such as diabetes and heart disease. For more information, see the following websites: University of Melbourne Stem Cell Laboratory: http://www.cns.unimelb.edu.au Monash Institute of Medical Research: http://www.monashinstitute.org Friedreich Ataxia Research Association: http://www.fara.org.au Friedreich Ataxia Research Alliance: http://www.curefa.org Credits Produced by Rebecca Scott Camera by Clive Banfield Editing by Rob Cross, Corporate Video Video of heart cells provided courtesy of: Duncan E Crombie. Senior Research Assistant Stem Cell Medicine, O #39;Brien Institute With thanks to: Dr. Alice Pébay Group Leader, Stem Cell Lab, Centre for Neuroscience and Dept of Pharmacology, The University of Melbourne Senior Research Fellow, O #39;Brien Institute Dr Mirella Dottori Group Leader, Stem Cell Lab. Centre for Neuroscience and Dept of Pharmacology, University of Melbourne Dr Paul Verma Senior Scientist, Head of the Reprogramming of Somatic Cells Lab, Centre for Reproduction and Development, Monash Institute of Medical Research Dr Jun Liu, Post-doc fellow Centre for Reproduction and Development, Monash Institute of Medical Research Ms Varlli Beetham, Executive Director, Friedreich #39;s Ataxia Research Association (FARA) Jessica Leung and the staff of the Stem Cell Lab, Centre for Neuroscience ...From:globotrashViews:1292 1ratingsTime:03:20More inPeople Blogs

Continued here:
University of Melbourne announce Stem Cells Discovery - Video

RGO Walking
T-6 Asia A Complete Injury. March 4 2011 is the date of my injury. I have had 2 stem cell treatments at Cell Medicine Institute, Panama City, Panama.From:TheBncfilmsViews:858 2ratingsTime:02:41More inEntertainment

Continued here:
RGO Walking - Video

Walk
Some video of me doing water therapy at Lawrence County physical therapy Institute in New Castle Pennsylvania. I also do gait training at Harmerville rehab center. My name is Chris Niles. I #39;m a T6 Asia A complete spinal cord injury. I was injured March 4, 2011. I have had two treatments of adult stem cell therapy at Cell Medicine, located in Panama City, Panama. I have made significant gains since participating in stem cell therapy. Improvements with body temperature regulation, blood pressure, lower back muscle regeneration, nerve pain reduction. I Have sensory sensation down to about my T10 in my back. I am looking to go for my third treatment of adult stem cells in 2012.From:Chris NilesViews:542 2ratingsTime:04:27More inPeople Blogs

See more here:
Walk - Video

Doctor Reviews: Cord Blood Banking and Rapidly Changing Medicine
Learn more about cord blood banking here: http://www.cordblood.com Meet Dr. Michael Chez, Director of Pediatric Neurology and Epilepsy at Sutter Neuroscience Institute in Sacramento, Calif. Dr. Chez has worked first-hand with patients who have undergone cord blood stem cell infusions as potential treatment for conditions like cerebral palsy. "I think we #39;re at the dawn of a very big leap in science with stem cell medicine," he says. According to Dr. Chez, recommending cord blood banking has become fairly standard in prenatal counseling. It #39;s also becoming normal to ask parents if they #39;ve banked when exploring potential treatment options for diseases and disorders that may be treated with cord blood. "Any friend of the family who asks me, I suggest they bank their baby #39;s cord blood," Dr. Chez adds. Cord blood has been successfully used for more than 20 years to treat many serious diseases like certain cancers and blood, immune, and metabolic disorders. Today, clinical trials are investigating new therapies using a child #39;s own cord blood stem cells for conditions that currently have no treatment, like hearing loss, traumatic brain injury, cerebral palsy, and juvenile diabetes. Several of these clinical trials only use stem cells from CBR as a way of ensuring consistent quality, offering CBR clients exclusive access to groundbreaking medicine. You can learn more about CBR #39;s role in advancing stem cell research through our Center for Regenerative Medicine, cordbloodregistry.com Use ...From:cordbloodregistryViews:667 8ratingsTime:01:44More inScience Technology

Continued here:
Doctor Reviews: Cord Blood Banking and Rapidly Changing Medicine - Video

Future Health Biobank Arabic video tour
Learn more about the services offered at Future Health: http://www.fhbb.ae Europe #39;s first accredited family stem cell bank and UK Queen #39;s Award winner, Future Health Biobank, is celebrating 10 years as a pioneer in the collection and cryopreservation of stem cells for potential future medical use with the news that it is opening a second laboratory in Switzerland to complement its established UK facility. The company, which is headquartered in Nottingham in the UK, was established to process and store cord blood stem cell samples for families in 2002 at a time when the idea of stem cell medicine was still more likely to be read about in science fiction books than in our daily newspapers and magazines. Future Health started by storing cord blood stem cells in 2003 and within four years it had stored its 10000th sample. Another five years on and the company #39;s purpose built cryogenic storage facility has over 50000 stem cell samples for families from more than 50 countries in its care. A cord tissue storage service was added in 2009 and now services to capture stem cells from other sources identified for potential medical use have been introduced. Future Health have also put time and resources into research. In the last four years the company have invested in a number of important study areas which could have an impact on the future effectiveness and use of stem cells in medical treatments. These include finding the optimum cryopreservation methods which maintain stem cell ...From:FHBioBankViews:140 0ratingsTime:13:05More inScience Technology

See the rest here:
Future Health Biobank Arabic video tour - Video

Audio Book Review: The Stem Cell Hope: How Stem Cell Medicine Can Change Our Lives by Alice Park ...
http://www.AudioBookMix.com This is the summary of The Stem Cell Hope How Stem Cell Medicine Can Change Our Lives by Alice Park (Author), Walter Dixon (Narrator).From:BookReviewsChanViews:3 0ratingsTime:01:27More inEntertainment

See the original post here:
Audio Book Review: The Stem Cell Hope: How Stem Cell Medicine Can Change Our Lives by Alice Park ... - Video

SAN DIEGO--(BUSINESS WIRE)--

Cytori Therapeutics, Inc. (CYTX) will give a company presentation at the 2012 Stem Cell Meeting on the Mesas Investor and Partnering Forum on Tuesday, October 30.

The following are specific details regarding Cytoris presentation at the conference:

1:45pm PT

The presentation will be recorded and will be available on the Webcasts page of the Cytoris investor relations site the week following the conference.

The Investor and Partnering Forum is being organized by the Alliance for Regenerative Medicine (ARM) and the California Institute for Regenerative Medicine to profile the industrys most exciting technologies.

About Cytori

Cytori Therapeutics, Inc. is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. Our scientific data suggest ADRCs improve blood flow, moderate the immune response and keep tissue at risk of dying alive. As a result, we believe these cells can be applied across multiple "ischemic" conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori's proprietary technologies and products, including the Celution system product family. http://www.cytori.com

The rest is here:
Cytori Therapeutics Announces Company Presentation the 2012 Stem Cell Meeting on the Mesa’s Investor and Partnering ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

bluebird bio, a leader in the development of innovative gene therapies for severe genetic disorders, announced today that the California Institute for Regenerative Medicine (CIRM) has approved an award to the company for $9.3 million for the first round of its new Strategic Partnership Awards initiative. The award is to support a Phase 1/2 study to evaluate the safety and efficacy of LentiGlobin, the companys development-stage program for the treatment of beta-thalassemia, which will be initiated in the United States in 2013.

We are very encouraged by the clinical data generated to date demonstrating the potential of LentiGlobin as a one-time transformative gene therapy for patients with beta-thalassemia, said David Davidson, M.D., chief medical officer, bluebird bio. bluebird bio has made significant advances in lentiviral vector design, transduction efficiency, and in our manufacturing process, enabling the production of gene-modified products that can be scaled and deployed for many different clinical indications. We are delighted that CIRM has chosen to recognize the importance of this innovative approach for the treatment of one of the most commonly inherited blood disorders, and we are excited to work with CIRM to continue the development of LentiGlobin in the U.S.

bluebird bios LentiGlobin product introduces a fully functional human beta-globin gene into the patient's own hematopoietic stem cells. These corrected stem cells ultimately produce fully functioning red blood cells. bluebird bio is currently conducting a Phase 1/2 trial examining the feasibility, safety and efficacy of LentiGlobin in the treatment of beta-thalassemia and sickle cell disease. Results of the first patient were reported in Nature in 2010, showing dramatic results, including stable expression of functional beta-globin resulting in transfusion independence which now extends for greater than four years following a single treatment.

This CIRM award is among the first awards under the agencys Strategic Partnership Awards initiative, which is designed to engage more effectively with industry and to increase outside investment in CIRM-funded stem cell research. The funding awards were made at the October 25, 2012 meeting of the stem cell agencys governing board, the Independent Citizens Oversight Committee (ICOC).

About CIRM

CIRM was established in November 2004 with the passage of Proposition 71, the California Stem Cell Research and Cures Act. The statewide ballot measure, which provided $3 billion in funding for stem cell research at California universities and research institutions, was overwhelmingly approved by voters, and called for the establishment of an entity to make grants and provide loans for stem cell research, research facilities, and other vital research opportunities. A list of grants and loans awarded to date may be seen here: http://www.cirm.ca.gov/for-researchers/researchfunding.

About bluebird bio

bluebird bio is developing innovative gene therapies for severe genetic disorders. At the heart of bluebird bios product creation efforts is its broadly applicable gene therapy platform for the development of novel treatments for diseases with few or no clinical options. The companys novel approach uses stem cells harvested from the patients own bone marrow into which a healthy version of the disease causing gene is inserted. bluebird bios approach represents a true paradigm shift in the treatment of severe genetic diseases by eliminating the potential complications associated with donor cell transplantation and potentially presenting a one-time transformative therapy using a patients own stem cells. bluebird bio has two later stage clinical products in development for childhood cerebral adrenoleukodystrophy (CCALD) and beta-thalassemia/sickle cell disease. Led by a world-class team, its operations are located in Cambridge, Mass., San Francisco and Paris, France. For more information, please visit http://www.bluebirdbio.com.

Excerpt from:
bluebird bio Awarded $9.3 Million From the California Institute for Regenerative Medicine to Further Gene Therapy ...

NEWARK, Calif., Oct. 26, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM) announced today that President and CEO Martin McGlynn will make a presentation on the Company's programs and operations at the 2nd Annual Investor and Partnering Forum during the 2012 Stem Cell Meeting on the Mesa to be held October 29 -31. Mr. McGlynn is scheduled to speak at 10:15 a.m. Pacific Time on Tuesday, October 30, at the Sanford Consortium for Regenerative Medicine in La Jolla, California.

The Stem Cell Meeting on the Mesa is a three-day conference organized by the Sanford Consortium for Regenerative Medicine, the California Institute for Regenerative Medicine (CIRM) and the Alliance for Regenerative Medicine (ARM). The goal of the conference is to bring together the scientific research and business development communities in regenerative medicine to advance stem cell science into cures for debilitating diseases and injuries. The meeting features a nationally recognized Scientific Symposium attended by leading scientists and researchers, as well as an Investor and Partnering Forum designed to facilitate a bridge between academia and industry through one-on-one meetings, furthering the translation of clinical research.

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC(R) cells (purified human neural stem cells), is currently in development as a potential treatment for a broad range of central nervous system disorders. In a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children, the Company has shown preliminary evidence of progressive and durable donor-derived myelination in all four patients transplanted with HuCNS-SC cells. The Company is also conducting a Phase I/II clinical trial in chronic spinal cord injury in Switzerland and recently reported positive interim data for the first patient cohort. The Company has also initiated a Phase I/II clinical trial in dry age-related macular degeneration (AMD), and is pursuing preclinical studies in Alzheimer's disease. StemCells also markets stem cell research products, including media and reagents, under the SC Proven(R) brand. Further information about StemCells is available at http://www.stemcellsinc.com.

The StemCells, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7014

Apart from statements of historical fact, the text of this press release constitutes forward-looking statements within the meaning of the U.S. securities laws, and is subject to the safe harbors created therein. These statements include, but are not limited to, statements regarding the clinical development of its HuCNS-SC cells; the Company's ability to commercialize drug discovery and drug development tools; and the future business operations of the Company. These forward-looking statements speak only as of the date of this news release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management's current views and are based on certain assumptions that may or may not ultimately prove valid. The Company's actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including those described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2011 and in its subsequent reports on Forms 10-Q and 8-K.

Read the original here:
StemCells, Inc. to Present at 2012 Stem Cell Meeting on the Mesa's Investor and Partnering Forum

MARLBOROUGH, Mass.--(BUSINESS WIRE)--

Advanced Cell Technology, Inc. (ACT; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that chairman and CEO Gary Rabin will present at the 2012 Stem Cell Meeting on the Mesas Investor and Partnering Forum, Oct. 29 and 30 in La Jolla, California.

In his presentation, Mr. Rabin will provide an overview of ACTs ocular programs. The presentation will be webcast by theAlliance for Regenerative Medicinein the weeks following the conference.

The following are specific details regarding ACTs presentation at the conference:

About the Stem Cell Meeting on the Mesas Investor and Partnering Forum

The Investor and Partnering Forum is being organized by the Sanford Consortium, CIRM and The Alliance for Regenerative Medicine (ARM) to facilitate translational research, promote engagement between the scientific and business communities and provide opportunities for business, academic research and investor participants to connect in one-on-one strategic partnering meetings. To learn more or to register for the 2011 Stem Cell Meeting on the Mesa Symposium and Investor & Partnering Forum, please visit http://www.stemcellmeetingonthemesa.com.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words will, believes, plans, anticipates, expects, estimates, and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the companys periodic reports, including the report on Form 10-K for the year ended December 31, 2011. Forward-looking statements are based on the beliefs, opinions, and expectations of the companys management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the companys management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Companys clinical trials will be successful.

Read more here:
Advanced Cell Technology to Present at Stem Cell Meeting on the Mesa’s 2nd Annual Investor and Partnering Forum